Background: Calprotectin is a marker of inflammation, but its clinical utility in dogs with chronic
| I N TR ODU C TI ON
Chronic inflammatory enteropathies (CIE) comprise an important group of disorders in dogs 1, 2 that are characterized by chronic persistent or recurrent gastrointestinal (GI) signs and histopathologic evidence of primary intestinal mucosal inflammation. 1, 3, 4 Based on the response to treatment, canine non-infectious CIE are classified as food-responsive enteropathy (FRE), antibiotic-responsive enteropathy (ARE), or steroid-/ immunosuppressant-responsive (or -refractory) enteropathy (SRE/ IRE).
1,2
A diagnosis of canine SRE/IRE can be challenging as it involves a comprehensive diagnostic investigation to exclude other causes of chronic GI signs (eg, hypoadrenocorticism, exocrine pancreatic insufficiency, endoparasites), to document mucosal inflammation based on histopathology, to demonstrate an inadequate clinical response to appropriately designed dietary and antibiotic treatment trials, and to
show clinical improvement with anti-inflammatory/immunosuppressive therapy (or lack thereof in refractory cases). [1] [2] [3] [4] The pathogenesis of canine SRE/IRE is poorly understood, and an impaired immunoregulation and overt inflammatory response against dietary and bacterial antigens appears to play a central role, together with the presence of a genetic predisposition. 3, 5 Recent advances in the diagnosis of CIE include the development of a 6-parameter 6 (considering the dog's attitude/activity, appetite, vomiting, feces consistency, feces frequency, and weight loss; the cumulative score can range from 0 to 18) and a 9-parameter clinical scoring system 7 (which considers the dog's attitude/activity, appetite, vomiting, feces consistency, feces frequency, weight loss, serum albumin concentration, ascites/peripheral edema, and pruritus; the cumulative score can range from 0 to 27), an endoscopic lesion score, 8 and a consensus for classifying CIE based on histopathologic criteria. 3, 9 However, only a few minimally or noninvasive biomarkers of inflammation have been evaluated in dogs with CIE, [10] [11] [12] [13] [14] [15] [16] [17] [18] none of which are currently routinely used in clinical practice.
Canine calprotectin, the S100A8/A9 protein complex, and also S100A12 are Ca 21 -binding proteins of the S100/calgranulin family that have been shown to be associated with acute and chronic inflammation and with malignant transformation. 5 These proteins are involved in the regulation of cell proliferation and metastasis, and after their extracellular release function as endogenous danger-signaling molecules (alarmins). 19 Calprotectin and S100A12 have potential as markers of inflammation in dogs. 11, 15, 16, [19] [20] [21] In canine CIE, the expression of mucosal S100-mRNA was shown to be increased 11-fold. 22 Fecal calprotectin and S100A12
have been shown to be correlated with the clinical disease activity, 15, 20, 21 and the latter also correlated with the severity of endoscopic lesions 15 and the response to treatment in dogs with CIE. 16 C-reactive protein (CRP) is a positive acute-phase protein of the pentraxin family that is produced by the liver in response to IL-6 and IL-1b during states of infection, inflammation, or cancer. 23 Serum CRP concentration has been suggested to serve as a marker of disease progression and response to treatment in dogs with SRE/IRE. 6, 10, 11 We hypothesized that fecal calprotectin concentrations (1) are associated with the severity of clinical signs, histologic lesions, or both (2) predict the response to different forms of treatment, and (3) correlate with the concentration of other biomarkers of intestinal inflammation. To prove or disprove these hypotheses, the objectives of our study were to evaluate fecal calprotectin concentrations in dogs with CIE in relation to (1) the severity of clinical signs and histologic lesions, and (3) the concentration of serum CRP and fecal S100A12. In addition, the possibility of an association between fecal calprotectin and the concentration of calprotectin and S100A12 in serum was tested.
| M A TER I A LS A N D M ETH OD S

| Ethics approval
The study design was reviewed and approved by the Clinical Research antibiotic trial for at least 10-14 days) were required to be performed to further characterize the disease process, 1,3 with a deviation from this scheme being allowed for dogs with very severe clinical signs or marked abnormal clinicopathologic findings (ie, hypoalbuminemia or panhypoproteinemia). 3, 7 The time point of GI tissue specimen collection was also at the clinician's discretion. Dogs were only included in the study if they had not received any anti-inflammatory/immunosuppressive treatment during the 2 weeks before enrollment and initial sample collection.
Exclusion criteria for the study that were applied retrospectively, were the lack of intestinal biopsies submitted from a dog or if intestinal biopsies submitted were of inadequate quality (n 5 90). Further, dogs were excluded if neoplasia was identified on GI histopathology (n 5 8).
Follow-up information was available from some dogs (n 5 32) using the same study questionnaire including a CCECAI scoring sheet, 
| Sample collection
Single whole blood (ethylenediaminetetraacetic acid was used as anticoagulant), serum, and urine specimens were collected from each dog at the first presentation for diagnostic work-up and, if a reevaluation was performed according to the study protocol, at the respective recheck(s). Whole blood and serum were collected after food was with- Follow-up data were included from dogs that were clinically reevaluated as described and sample sets were collected at the time of recheck evaluation.
| Sample analyses
Whole blood was used for routine hematology (performed at the insti- 26 and used for statistical analyses. Fecal and serum S100A12 concentrations were measured by a species-specific in-house sandwich ELISA, 28 and the 3-day mean fecal S100A12 concentration was also calculated and used for analyses.
| Histopathologic evaluation of gastrointestinal tissue biopsies
Histopathologic evaluation of GI tissue biopsies was performed by 1 of Standardization grading system. 3 The severity of morphologic lesions and inflammatory changes in the duodenum, ileum, and colon were recorded using a 4-point grading system (0 5 normal, 1 5 mild lesions, 2 5 moderate lesions, and 3 5 severe lesions). Individual and cumulative lesion scores (calculated as the sum of individual lesion scores)
were considered for statistical analyses. Gastric biopsies were evaluated to rule out evidence of neoplastic disease, but inflammatory changes were not graded. Of the 32 dogs with CIE from which follow-up information was available, 19 dogs were diagnosed with SRE/IRE and 13 dogs with FRE or ARE ( Figure 1 , Table 1 ). In the FRE group, an easily digestible diet was given to 2 dogs, a novel protein diet to 2 dogs, and a diet containing hydrolyzed protein to 4 dogs; 1 FRE dogs was given a home- Fecal calprotectin concentrations were correlated with fecal S100A12 concentrations (q 5 0.90, P corr < .0006), but showed no association with serum concentrations of CRP (q 5 0.16, P corr 5 .71), calprotectin (q 5 0.14, P corr 5 1.00), or S100A12 (q 5 0.09, P corr 5 1.00) ( Table 2 ).
| Data analyses
| Fecal calprotectin concentrations and other biomarkers
| Fecal calprotectin concentrations and clinical disease severity
Three-day mean fecal calprotectin concentrations were weakly correlated with the CCECAI score at the time of enrollment (q 5 0.27, P corr 5 .039).
| Other biomarkers and clinical disease severity
Correlation with the CCECAI score was also seen for serum CRP concentrations (q 5 0.42, P corr < .0006), but not for fecal S100A12 concentrations (q 5 0.24, P corr 5 .097). and with the overall cumulative inflammatory lesion score (q 5 0.52, P 5 .018; Table 2 ), whereas the correlation with the lamina propria lymphoplasmacytic infiltration (q 5 0.41, P corr 5 .14) and the overall inflammatory lesion score in the ileum (q 5 0.38, P corr 5 .08) did not remain significant after correction for multiple comparisons.
| Other biomarkers and microscopic lesion severity
Serum CRP concentrations were associated with the severity of morphologic lesions in the duodenum (Table 2 ). However, there was no significant correlation between serum CRP concentrations and the severity of microscopic lesions in the ileum or colon; neither did serum CRP concentrations correlate with the cumulative histologic lesion scores ( Table 2 ). Fecal S100A12 concentrations were significantly correlated with the number of duodenal lamina propria intraepithelial lymphocytes (q 5 0.30, P corr 5 .017), whereas the relationship with other inflammatory criteria did not reach significance (Table 2 ). Figure 2 ).
| Fecal calprotectin concentrations and disease classification
| Other biomarkers and disease classification
A serum CRP concentration of 9.1 mg/L had a sensitivity of 72%
(95%CI: 47%-90%) and a specificity of 100% (95%CI: 74%-100%;
AUROC: 83%, 95%CI: 68%-98%) for the diagnosis of SRE/IRE versus FRE/ARE, whereas a CCECAI score of 8 had a sensitivity of 68% (95%CI: 44%-87%) and a specificity of 92% (95%CI: 64%-100%; AUROC: 82%, 95%CI: 68%-96%) to distinguish these 2 groups of dogs.
A combination of at least 2 of these markers yielded an increased sensitivity (about 80%), the highest sensitivity, and specificity being reached for the combination of fecal calprotectin and serum CRP concentration (78% and 100%, respectively; Table 3 ).
| Fecal calprotectin concentrations and response to treatment
Fecal calprotectin concentrations were also numerically higher in dogs diagnosed with SRE/IRE that showed only PR or NR (median: 53%-100%) ( Table 3) . Whether fecal calprotectin can also distinguish Relationship between the 3-day mean fecal calprotectin concentrations and the clinical disease activity (CCECAI) score, concentrations of other inflammatory markers (serum CRP, serum and 3-day mean fecal S100A12, and serum calprotectin), and the severity of morphologic and inflammatory histologic lesions in the duodenum, ileum, and colon in dogs with CIE (n 5 127). Abbreviations: LPC, lymphocytes/plasma cells; MU, macrophages; N/A, not applicable; P corr , Bonferroni corrected P value (P corr 5 P 3 n). 19 Calprotectin has also been shown to be stable in naturally passed fecal samples for at with chronic diarrhea where higher CCECAI scores were associated with higher fecal calprotectin concentrations and a fecal calprotectin concentration 48.9 lg/g predicted severe clinical signs (CCECAI scores 12) with moderate sensitivity and high specificity. 20 Our results also agree with studies in children and human adults with IBD, 33, 35, [42] [43] [44] [45] [46] where the correlation between fecal calprotectin and clinical disease activity indices was shown to be generally weaker in dogs with CD 33, 35, 45 than in those with UC.
42-45
The minimum amount of time that clinical signs had to be present was 2-3 weeks, which is slightly shorter than the time reported in the 2010 consensus statement. 3 The inclusion of dogs in the study when GI signs were noticeable to the owner for at least 2 weeks (n 5 4 dogs, 3%) was considered an appropriate criterion for dogs with severe clinical signs or marked clinicopathologic findings (ie, hypoalbuminemia/ panhypoproteinemia and hypocobalaminemia, both of which were shown to be negative prognostic factors 100 and 170 lg/g had strong predictive value for histologic remission. 44, 45, 47, 48 These findings suggest that fecal calprotectin testing could be a good surrogate marker to evaluate disease severity.
Fecal calprotectin concentrations were correlated with histologic inflammatory lesions, particularly lamina propria lymphocytes in the ileum, but not with the number of intestinal lamina propria neutrophils and macrophage(s) (MU) (especially in the colon). The latter was an unexpected finding as calprotectin is predominantly expressed by activated neutrophils and MU 19, 49 and because calprotectin correlates with the number of infiltrating neutrophils in human IBD. 50 A possible explanation could be that, while the inflammatory infiltrate in canine CIE is primarily lymphoplasmacytic with an eosinophilic component in some cases, neutrophils and eosinophils can be very difficult to identify depending on tissue processing and staining. 51, 52 In line with this, histopathologic changes (primarily the number of T lymphocytes in the lamina propria) poorly correlate with clinical disease or response to treatment. [53] [54] [55] An alternative explanation for this finding could be that calprotectin expression does not merely reflect the number of intestinal lamina propria neutrophils and MU, but rather reflects the activity of these cells. In human IBD, it is believed that activated MU contribute to the production of inflammatory cytokines that lead to altered chemotactic signals and an increased recruitment of lymphocytes. 56 In dogs with CIE, only few cytokines have been evaluated based on mRNA analysis and the results have been inconsistent. 57, 58 However, 35, 44, 45, 63 and is also similar to the results reported for fecal S100A12 concentrations in dogs. 16 The current study suggests that a pretreatment fecal calprotectin concentration of 44 or to predict sustained clinical remission over 1 year. 65, 66 This finding also agrees with the results for fecal S100A12 in dogs with CIE where fecal S100A12 concentrations 2,700 ng/g identified dogs with IBD that were refractory to anti-inflammatory/immunosuppressive treatment. 16 In the present study, the diagnostic accuracy of fecal calprotectin to predict PR/NR was also superior to that of serum CRP and the CCECAI score, and the lack of a relationship between clinical disease severity and outcome contrasts the findings of other studies that showed the individual outcome to be significantly associated with higher clinical disease activity scores. The present study aimed to determine the value of measuring fecal calprotectin concentrations in dogs with intestinal inflammatory lesions, and dogs diagnosed with GI cancer were excluded from the study.
However, increased fecal calprotectin concentrations have also been detected in people with GI malignancies, 67, 68 and the possibility that fecal calprotectin concentrations are also altered in dogs with alimentary neoplasms cannot be excluded. Thus, further evaluation of fecal calprotectin concentrations in canine GI neoplasia is warranted. Until more data is available, fecal calprotectin might be seen as a good surrogate biomarker of GI inflammation but will not be a replacement for biopsy or other clinicopathologic tests.
Our study had some limitations. First, the clinical response to treatment was used as the primary endpoint of the study, and the possibility of a correlation with mucosal healing (deep remission) was not evaluated. Second, single spot fecal samples were used to measure fecal calprotectin concentrations, but the biological variation of fecal calprotectin concentrations has only been estimated in a small number of dogs with CIE. 24 Third, long-term outcome (ie, a follow-up period of >12 months) was not evaluated in the majority of dogs in our study.
Fourth, the small sample size in subgroup analyses (ie, disease classification and response to treatment) has the potential for a type I or type II error. Fifth, several different clinicians were involved in evaluating the CCECAI score, which may add some variability. However, the CCE-CAI scoring system is 1 of the 2 standardized semi-objective methods for evaluation of clinical disease severity in dogs with chronic enteropathies, and it has been used in a number of investigations. Further, histopathologic evaluation of GI tissue biopsies was performed by 1 of 7 different pathologists (though with a special expertise in GI pathology) and interobserver variability exists even with the use of standardized criteria. 69 Further, given the multicenter nature of our clinical observational study, it was not feasible to standardize treatment and follow-up for all dogs, and some flexibility in the diagnostic evaluation was needed to accommodate dogs with severe clinical signs, marked clinicopathological abnormalities (eg, severe hypoalbuminemia), or both. Also, choices and doses of immunosuppressives were not standardized in our study. Lastly, the possibility of missing a diffusely infiltrating neoplasm (ie, alimentary lymphoma) in dogs diagnosed with CIE cannot be excluded as biopsies were not available from all section of the GI tract in all dogs and because endoscopy does not allow evaluation of the entire small intestine.
| CON CL U S I ONS
We conclude that fecal calprotectin appears to be a potentially useful 
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